Table 1:
Baseline characteristics of patients on KRT receiving molnupiravir or sotrovimab.
| OpenSAFELY-UKRR cohort | SRR cohort | |||||
|---|---|---|---|---|---|---|
| Characteristics | Molnupiravir group | Sotrovimab group | Total | Molnupiravir group | Sotrovimab group | Total |
| Patients, n | 515 | 1852 | 2367 | 270 | 723 | 993 |
| Age (years), mean (SD) | 55.5 (14.6) | 56.0 (14.6) | 55.9 (14.6) | 54.7 (12.7) | 58.4 (14.2) | 57.4 (13.9) |
| Female, n (%) | 217 (42.1) | 813 (43.9) | 1030 (43.5) | 113 (41.9) | 310 (42.9) | 423 (42.6) |
| White, n (%) | 452 (87.9) | 1567 (84.7) | 2019 (85.4) | |||
| Most deprived, n (%) | 75 (14.9) | 282 (15.7) | 357 (15.6) | 36 (13.3) | 195 (27.0) | 231 (23.3) |
| Region (NHS), n (%) | ||||||
| East | 144 (28.0) | 489 (26.4) | 633 (26.7) | |||
| London | 36 (7.0) | 148 (8.0) | 184 (7.8) | |||
| East Midlands | 35 (6.8) | 357 (19.3) | 392 (16.6) | |||
| West Midlands | 9 (1.8) | 58 (3.1) | 67 (2.8) | |||
| North East | 6 (1.2) | 67 (3.6) | 73 (3.1) | |||
| North West | 45 (8.7) | 183 (9.9) | 228 (9.6) | |||
| South East | 61 (11.8) | 92 (5.0) | 153 (6.5) | |||
| South West | 92 (17.9) | 294 (15.9) | 386 (16.3) | |||
| Yorkshire | 87 (16.9) | 164 (8.9) | 251 (10.6) | |||
| KRT modality, n (%) | ||||||
| Dialysis | 131 (25.4) | 588 (31.8) | 719 (30.4) | 21 (7.8) | 324 (44.8) | 345 (34.7) |
| Kidney transplant | 384 (74.6) | 1264 (68.3) | 1648 (69.6) | 249 (92.2) | 399 (55.2) | 648 (65.3) |
| Years since KRT start, median (IQR) | 7 (4–13) | 7 (4–12) | 7 (4–13) | 12 (4–18) | 9 (2–14) | 10 (3–15) |
| High-risk cohorts, n (%) | ||||||
| Down syndrome | ≤5 | ≤5 | ||||
| Solid cancer | 28 (5.4) | 61 (3.3) | 89 (3.8) | |||
| Haematological disease | 12 (2.3) | 61 (3.3) | 73 (3.1) | |||
| Liver disease | ≤5 | 29 (1.6) | ||||
| Immune-mediated inflammatory diseases | 222 (43.1) | 681 (36.8) | 903 (38.2) | |||
| Immunosuppression | 17 (3.3) | 57 (3.1) | 74 (3.1) | |||
| HIV/AIDS | ≤5 | 6 (0.3) | ||||
| Rare neurological disease | ≤5 | 6 (0.3) | ||||
| BMI (kg/m2), mean (SD) | 28.4 (6.1) | 28.3 (6.1) | 28.3 (6.1) | |||
| Comorbidities, n (%) | ||||||
| Diabetes | 189 (36.7) | 710 (38.3) | 899 (38.0) | |||
| Chronic cardiac disease | 111 (21.6) | 506 (27.3) | 617 (26.1) | |||
| Hypertension | 447 (86.8) | 1585 (85.6) | 2032 (85.9) | |||
| Chronic respiratory disease | 94 (18.3) | 365 (19.7) | 459 (19.4) | |||
| Vaccination status, n (%) | ||||||
| None | 9 (1.8) | 28 (1.5) | 37 (1.6) | 0 (0.0) | 16 (2.2) | 16 (1.6) |
| 1–2 | 31 (6.0) | 108 (5.8) | 139 (5.9) | 3 (1.1) | 46 (6.4) | 49 (4.9) |
| ≥3 | 475 (92.2) | 1716 (92.7) | 2191 (92.6) | 267 (98.9) | 661 (91.4) | 928 (93.5) |
| Days between test positive and treatment, median (IQR) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–2) | 2(1–3) | 2 (1–3) |
| Weeks between 16 December 2021 and treatment, median (IQR) | 12 (4–17) | 15 (8–22) | 14 (7–21) | 15 (8–26) | 13 (9–23) | 13 (9–24) |
| Primary renal diagnosis, n (%) | ||||||
| Diabetes | 34 (12.6) | 129 (17.8) | 163 (16.4) | |||
| Glomerulonephritis | 71 (26.3) | 164 (22.7) | 235 (23.7) | |||
| Interstitial | 113 (41.9) | 219 (30.3) | 332 (33.4) | |||
| Multisystem | 32 (11.9) | 115 (15.9) | 147 (14.8) | |||
| Unknown (including missing) | 20 (7.4) | 96 (13.3) | 116 (11.7) | |||
In the OpenSAFELY-UKRR cohort, KRT start time, IMD, BMI, ethnicity and positive test date had 617, 73, 181, ≤5 and 199 missing values, respectively. In the SRR cohort, 17 postcodes did not match to an SIMD category and 12 primary renal diagnosis codes within the unknown group were missing.